POLE and glioblastoma: Prior case reports demonstrated response to ICI monotherapy (pembrolizumab or atezolizumab) in POLE-mutated glioblastoma.4,5 Although there is no specific study of bevacizumab monotherapy in POLE-mutated glioblastoma, the duration of response in our patient (15 months) was longer than that typically seen with bevacizumab monotherapy (~4 months from the BRAIN study6) in recurrent unselected glioblastoma.